The licence expressly extends to all sub-Saharan African countries as licensed territory. No African entity is a party; the nexus is territorial.
| Record ID | TX-AFR-2025-0004 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Licence extension, Patent licence, Non-exclusive licence |
| IP rights | patent, know-how |
| Status | Announced |
| Qualifying date | 2025-07-14 |
| Sector | Life sciences · Pharmaceuticals – HIV |
| African markets | Multi-jurisdictional |
| Licensed territory | 133 countries including all least-developed countries, all low-income countries, all lower-middle-income countries and all sub-Saharan African countries, plus countries where ViiV holds no cabotegravir patents. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, single · 1 source(s) |
| Last verified | 2026-10-25 |
Parties
- ViiV Healthcare (United Kingdom): licensor
- MPP (Switzerland): licensor, intermediary
Key terms
- Interest: non-exclusive licence to develop, manufacture and supply; Exclusivity: non-exclusive; Territorial scope: 133 countries including all sub-Saharan African countries; Field of use: Treatment of HIV-1 infection in adults and adolescents weighing at least 35 kg
Sources
- ViiV Healthcare and Medicines Patent Pool extend voluntary licensing agreement to enable access to long-acting injectable HIV treatment, Medicines Patent Pool, 2025-07-14
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.
